国产热热热精品,亚洲视频久久】日韩,三级婷婷在线久久,99人妻精品视频,精品九热人人肉肉在线,AV东京热一区二区,91po在线视频观看,久久激情宗合,青青草黄色手机视频

News >Bizchina

New R&D center tackles diabetes

2010-11-04 14:33

New R&D center tackles diabetes

A researcher at an Eli Lilly laboratory in Suzhou, Jiangsu province. The US company hopes to expand its research capabilities in Shanghai with the opening of its new diabetes research and development center. [Photo/China Daily]

BEIJING - US-based pharmaceutical company Eli Lilly and Company announced on Tuesday the establishment of a diabetes research center in Shanghai and the hiring of 100 scientific and support staff, most of whom will be domestic hires.

The center will officially open in the second half of 2011, said Jan Lundberg, executive vice-president of Science and Technology of Lilly and president of Lilly Research Laboratories.

It aims to meet China's growing demand for innovative diabetes medicine that suits local patients.

"This center will complement our existing network of collaborations in China and also will enable us to further gain the insights of China's talented scientists," he said.

The company already has an R&D facility in Zhangjiang Hi-tech Park, Shanghai.

In 2003, Lilly started cooperating with Shanghai ChemExplorer Co Ltd, a local medical R&D outsourcing company.

The two sides also set up PharmaExplorer and BioExplorer, providing exclusive services for Lilly.

According to a recent article in The New England Journal of Medicine, about 92 million Chinese people (around 10 percent of the nation's adult population), have diabetes and the number of patients is expected to increase in the next decade.

"Lilly's presence in China spans every aspect of our business, from R&D to manufacturing to sales to marketing," said Jacques Tapiero, senior vice-president of Lilly and president of Lilly's Emerging Market Business Area.

He added that the drugmaker will focus not only on first-tier cities but also on second and third-tier cities where the number of diabetes patients is also increasing fast.

Lilly entered China in 1993 with operations and research facilities in Shanghai. According to Eric Baclet, president of Lilly China, Lilly's payroll in China doubled during the past two years to 3,000.

It also established a venture capital fund in 2007 called Lilly Asian Ventures to invest in China's biopharmaceutical industry.

According to Tapiero, given the growing demand for diabetes medicine in China, Lilly plans to surpass the 24-25 percent average annual growth of the nation's pharmaceutical market.

Related News:

天柱县| 汤原县| 淄博市| 眉山市| 宣威市| 电白县| 霍邱县| 平泉县| 海晏县| 琼海市| 岳西县| 高清| 久治县| 扎囊县| 无棣县| 宿州市| 甘孜| 雅江县| 大田县| 鄯善县| 新密市| 左权县| 浦县| 巴彦淖尔市| 重庆市| 彭泽县| 尖扎县| 樟树市| 榆林市| 阿尔山市| 蒲城县| 杨浦区| 个旧市| 元氏县| 巨野县| 华蓥市| 无极县| 政和县| 渝中区| 鄯善县| 通榆县|